Cellectis Statistics
Total Valuation
Cellectis has a market cap or net worth of $227.37 million. The enterprise value is $123.59 million.
Important Dates
The last earnings date was Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cellectis has 72.60 million shares outstanding. The number of shares has increased by 2.78% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 72.60M |
| Shares Change (YoY) | +2.78% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 2.19% |
| Owned by Institutions (%) | 16.34% |
| Float | 46.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.03 |
| Forward PS | 3.05 |
| PB Ratio | 3.79 |
| P/TBV Ratio | 3.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 1.37.
| Current Ratio | 1.52 |
| Quick Ratio | 1.49 |
| Debt / Equity | 1.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.42 |
Financial Efficiency
Return on equity (ROE) is -76.34% and return on invested capital (ROIC) is -15.73%.
| Return on Equity (ROE) | -76.34% |
| Return on Assets (ROA) | -8.43% |
| Return on Invested Capital (ROIC) | -15.73% |
| Return on Capital Employed (ROCE) | -28.49% |
| Weighted Average Cost of Capital (WACC) | 16.19% |
| Revenue Per Employee | $328,000 |
| Profits Per Employee | -$293,581 |
| Employee Count | 229 |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -377,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +107.38% in the last 52 weeks. The beta is 2.72, so Cellectis's price volatility has been higher than the market average.
| Beta (5Y) | 2.72 |
| 52-Week Price Change | +107.38% |
| 50-Day Moving Average | 3.71 |
| 200-Day Moving Average | 3.80 |
| Relative Strength Index (RSI) | 29.77 |
| Average Volume (20 Days) | 37,139 |
Short Selling Information
The latest short interest is 337,444, so 0.61% of the outstanding shares have been sold short.
| Short Interest | 337,444 |
| Short Previous Month | 364,178 |
| Short % of Shares Out | 0.61% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 14.46 |
Income Statement
In the last 12 months, Cellectis had revenue of $75.11 million and -$67.23 million in losses. Loss per share was -$0.67.
| Revenue | 75.11M |
| Gross Profit | 75.11M |
| Operating Income | -44.06M |
| Pretax Income | -67.61M |
| Net Income | -67.23M |
| EBITDA | -32.75M |
| EBIT | -44.06M |
| Loss Per Share | -$0.67 |
Full Income StatementBalance Sheet
The company has $185.42 million in cash and $82.34 million in debt, with a net cash position of $103.09 million or $1.42 per share.
| Cash & Cash Equivalents | 185.42M |
| Total Debt | 82.34M |
| Net Cash | 103.09M |
| Net Cash Per Share | $1.42 |
| Equity (Book Value) | 59.92M |
| Book Value Per Share | 0.83 |
| Working Capital | 70.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$37.65 million and capital expenditures -$2.23 million, giving a free cash flow of -$39.88 million.
| Operating Cash Flow | -37.65M |
| Capital Expenditures | -2.23M |
| Depreciation & Amortization | 10.93M |
| Net Borrowing | -17.09M |
| Free Cash Flow | -39.88M |
| FCF Per Share | -$0.55 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -58.66% and -89.51%.
| Gross Margin | 100.00% |
| Operating Margin | -58.66% |
| Pretax Margin | -90.01% |
| Profit Margin | -89.51% |
| EBITDA Margin | -43.60% |
| EBIT Margin | -58.66% |
| FCF Margin | n/a |
Dividends & Yields
Cellectis does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.78% |
| Shareholder Yield | -2.78% |
| Earnings Yield | -29.57% |
| FCF Yield | -17.54% |
Analyst Forecast
The average price target for Cellectis is $7.60, which is 145.96% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.60 |
| Price Target Difference | 145.96% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -9.97% |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cellectis has an Altman Z-Score of -1.07 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.07 |
| Piotroski F-Score | 2 |
